Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Multicenter, Open-Label Study of 89Zr-girentuximab for PET/CT Imaging of Tumors Likely to Express High Levels of CAIX

NCT05563272 is registered in ClinicalTrials.gov with Telix Pharmaceuticals (Innovations) Pty Ltd as lead sponsor.

NCT NCT05563272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05563272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Multicenter, Open-Label Study of 89Zr-girentuximab for PET/CT Imaging of Tumors Likely to Express High Levels of CAIX
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Ltd
Phase
Phase 2
Overall status
Terminated
Start date
June 6, 2023
Completion date
May 9, 2025
Enrollment
11 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, bladder urothelial carcinoma, cervical cancer, cholangiocarcinoma, colorectal cancer, epithelial ovarian cancer, esophageal cancer, gastric adenocarcinoma, gastric cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, hepatocellular carcinoma, malignant mesothelioma (mm), nasopharyngeal carcinoma, non small cell lung cancer, pancreatic ductal adenocarcinoma, small cell lung cancer, soft tissue sarcoma, von hippel lindau